Valmark Advisers Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 1.9% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,788 shares of the company’s stock after purchasing an additional 161 shares during the period. Valmark Advisers Inc.’s holdings in Merck & Co., Inc. were worth $740,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the company. Titan Capital Management LLC CA bought a new stake in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $25,000. LFA Lugano Financial Advisors SA boosted its position in Merck & Co., Inc. by 250.0% in the 2nd quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock valued at $26,000 after buying an additional 225 shares during the last quarter. JJJ Advisors Inc. bought a new position in Merck & Co., Inc. in the 2nd quarter valued at $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. in the 2nd quarter valued at $40,000. Finally, Fusion Family Wealth LLC boosted its position in Merck & Co., Inc. by 268.2% in the 2nd quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock valued at $41,000 after buying an additional 354 shares during the last quarter. 74.64% of the stock is currently owned by institutional investors.
Shares of NYSE:MRK traded up $0.45 during midday trading on Friday, hitting $85.01. The company had a trading volume of 4,464,874 shares, compared to its average volume of 8,993,708. Merck & Co., Inc. has a 12 month low of $70.89 and a 12 month high of $87.35. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 0.84. The stock has a market cap of $214.17 billion, a price-to-earnings ratio of 19.59, a PEG ratio of 1.83 and a beta of 0.54. The firm has a fifty day simple moving average of $83.94 and a 200 day simple moving average of $83.01.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $1.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion for the quarter, compared to analyst estimates of $11.59 billion. During the same period last year, the company earned $1.19 EPS. The firm’s revenue was up 14.9% on a year-over-year basis. Equities analysts forecast that Merck & Co., Inc. will post 5.16 EPS for the current fiscal year.
A number of brokerages have commented on MRK. ValuEngine lowered Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Mizuho increased their price objective on Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. set a $96.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, October 10th. Morgan Stanley increased their price objective on Merck & Co., Inc. from $90.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Societe Generale set a $105.00 price objective on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $95.35.
Merck & Co., Inc. Profile
Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.
Further Reading: Trading Penny Stocks
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.